NEW YORK (GenomeWeb) – Cell-and bead-based screening technologies firm IntelliCyt has closed a $2.5 million secured term loan agreement and a $1.5 million revolving line of credit from Oxford Finance, the financing firm announced today.

Albuquerque, NM-based IntelliCyt will use the debt facility for working capital, as well as product development and marketing. The company develops high-throughput, high-content screening products for phenotypic drug discovery, antibody discovery, and in vivo toxicity testing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.